Defending data-monitoring committees.
D016907:Adverse Drug Reaction Reporting Systems; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control*; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000517:prevention & control*; D003627:Data Interpretation, Statistical; D016903:Drug Monitoring / Q000706:statistics & numerical data*; D004992:Ethics, Medical; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States
D016588:Anticarcinogenic Agents; D013629:Tamoxifen